Qube Research & Technologies (QRT)’s Y-mAbs Therapeutics YMAB Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,249	Closed	-$42.6K	–	4941
2023 Q4	$42.6K	Buy	+6,249	New	+$36.1K	﹤0.01%	3345
2023 Q1	–	Sell	-25,966	Closed	-$127K	–	3108
2022 Q4	$127K	Sell	25,966 -2,285	-8%	-$16.6K	﹤0.01%	1945
2022 Q3	$407K	Buy	+28,251	New	+$468K	﹤0.01%	1539
2022 Q1	–	Sell	-15,577	Closed	-$253K	–	3100
2021 Q4	$253K	Buy	+15,577	New	+$333K	﹤0.01%	1876
2021 Q2	–	Sell	-10,433	Closed	-$315K	–	2875
2021 Q1	$315K	Buy	+10,433	New	+$428K	0.01%	1432
2020 Q3	–	Sell	-13,111	Closed	-$566K	–	2170
2020 Q2	$566K	Buy	+13,111	New	+$496K	0.01%	1065
2020 Q1	–	Sell	-7,588	Closed	-$237K	–	1743
2019 Q4	$237K	Buy	+7,588	New	+$225K	0.01%	1325

Other funds holding YMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT)'s YMAB Position: Q1 2024 in Review

Qube Research & Technologies (QRT) sold out of Y-mAbs Therapeutics (YMAB) in Q1 2024, closing a stake of 6,249 shares — an estimated $42.6K sold.

Qube Research & Technologies (QRT) first reported a position in YMAB in Q4 2019 and held it in 7 quarters. The position peaked at $566K in Q2 2020. 96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

Qube Research & Technologies (QRT) reported no remaining Y-mAbs Therapeutics position as of Q1 2024 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 6,249 Y-mAbs Therapeutics shares in Q1 2024, an estimated $42.6K.
Qube Research & Technologies (QRT) first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 7 quarters.
Qube Research & Technologies (QRT)'s Y-mAbs Therapeutics position peaked at $566K in Q2 2020.
96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2024, filed 14 May 2024.